Literature DB >> 18003782

Transglutaminase inhibition reduces fibrosis and preserves function in experimental chronic kidney disease.

Tim S Johnson1, Marie Fisher, John L Haylor, Zoe Hau, N James Skill, Richard Jones, Robert Saint, Ian Coutts, Melissa E Vickers, A Meguid El Nahas, Martin Griffin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18003782     DOI： 10.1681/ASN.2006070690

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  42 in total

1.  Transglutaminase 2 in pulmonary and cardiac tissue remodeling in experimental pulmonary hypertension.

Authors:  Krishna C Penumatsa; Deniz Toksoz; Rod R Warburton; Mousa Kharnaf; Ioana R Preston; Navin K Kapur; Chaitan Khosla; Nicholas S Hill; Barry L Fanburg
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-03       Impact factor: 5.464

2.  Endostatin and transglutaminase 2 are involved in fibrosis of the aging kidney.

Authors:  Chi Hua Sarah Lin; Jun Chen; Zhongtao Zhang; Gail V W Johnson; Arthur J L Cooper; Julianne Feola; Alexander Bank; Jonathan Shein; Heli J Ruotsalainen; Taina A Pihlajaniemi; Michael S Goligorsky
Journal:  Kidney Int       Date:  2016-04-14       Impact factor: 10.612

3.  Inhibition of transglutaminase 2, a novel target for pulmonary fibrosis, by two small electrophilic molecules.

Authors:  Keith C Olsen; Amali P Epa; Ajit A Kulkarni; R Matthew Kottmann; Claire E McCarthy; Gail V Johnson; Thomas H Thatcher; Richard P Phipps; Patricia J Sime
Journal:  Am J Respir Cell Mol Biol       Date:  2014-04       Impact factor: 6.914

4.  A crucial sequence for transglutaminase type 2 extracellular trafficking in renal tubular epithelial cells lies in its N-terminal beta-sandwich domain.

Authors:  Che-Yi Chou; Andrew J Streets; Philip F Watson; Linghong Huang; Elisabetta A M Verderio; Timothy S Johnson
Journal:  J Biol Chem       Date:  2011-06-07       Impact factor: 5.157

Review 5.  Cellular functions of tissue transglutaminase.

Authors:  Maria V Nurminskaya; Alexey M Belkin
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

Review 6.  Matrix metalloproteinases, atherosclerosis, proteinuria and kidney disease: Linkage-based approaches.

Authors:  G Dimas; F Iliadis; D Grekas
Journal:  Hippokratia       Date:  2013-10       Impact factor: 0.471

7.  Syndecan-4 knockout leads to reduced extracellular transglutaminase-2 and protects against tubulointerstitial fibrosis.

Authors:  Alessandra Scarpellini; Linghong Huang; Izhar Burhan; Nina Schroeder; Muriel Funck; Timothy S Johnson; Elisabetta A M Verderio
Journal:  J Am Soc Nephrol       Date:  2013-12-19       Impact factor: 10.121

8.  Transglutaminase 2 and its role in pulmonary fibrosis.

Authors:  Keith C Olsen; Ramil E Sapinoro; R M Kottmann; Ajit A Kulkarni; Siiri E Iismaa; Gail V W Johnson; Thomas H Thatcher; Richard P Phipps; Patricia J Sime
Journal:  Am J Respir Crit Care Med       Date:  2011-06-23       Impact factor: 21.405

Review 9.  Transglutaminse 2 and EGGL, the protein cross-link formed by transglutaminse 2, as therapeutic targets for disabilities of old age.

Authors:  William Bains
Journal:  Rejuvenation Res       Date:  2013-12       Impact factor: 4.663

Review 10.  Dissecting fibrosis: therapeutic insights from the small-molecule toolbox.

Authors:  Carmel B Nanthakumar; Richard J D Hatley; Seble Lemma; Jack Gauldie; Richard P Marshall; Simon J F Macdonald
Journal:  Nat Rev Drug Discov       Date:  2015-09-04       Impact factor: 84.694
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.